Results
“Championing collective justice for injured and defrauded Americans through fierce advocacy, integrity, and fearless representation against the world's most powerful entities.”
eJustice and its lawyers have been instrumental in litigation that has resulted in billions of dollars in recoveries and resolutions for injured and defrauded Americans.
The matters below reflect experience involving major pharmaceutical, medical-device, automotive, asbestos, consumer-product, and mass-tort litigation. For individual matters, the overall settlement or resolution of the litigation is distinguished from recoveries specifically attributable to eJustice, its lawyers, team members, or litigation partners.
AVANDIA
$3.4 BILLION SETTLEMENT
The Avandia MDL was formed on October 16, 2007, after studies suggested that the drug raised cardiovascular risks.
The litigation resulted in massive financial resolutions, including a $3.4 billion settlement in 2011 and billions in federal penalties.
BAYCOL
MORE THAN $1.16 BILLION IN SETTLEMENT PROGRAMS
The Baycol Product Liability Litigation was a federal proceeding centralized in the District of Minnesota involving thousands of claims against Bayer and GlaxoSmithKline over severe injuries and deaths.
Bayer resolved thousands of these claims through massive settlement programs totaling more than $1.16 billion.
VIOXX
$4.85 BILLION GLOBAL SETTLEMENT
Merck voluntarily pulled Vioxx from the market in September 2004 after clinical data revealed that it doubled the risk of serious cardiovascular events, including heart attacks and strokes.
In 2007, Merck agreed to a $4.85 billion global settlement program to resolve federal and state claims for patients who suffered heart attacks or strokes.
ACTOS
$2.37–$2.4 BILLION GLOBAL SETTLEMENT
The Actos multidistrict litigation was a massive consolidation of federal lawsuits against Takeda Pharmaceuticals over claims that the diabetes drug Actos increased the risk of bladder cancer.
Takeda reached a $2.37 billion to $2.4 billion global settlement in 2015 to resolve roughly 9,000 bladder cancer claims, contingent upon high participation rates from claimants.
FEN-PHEN / DIET DRUGS
MULTIBILLION-DOLLAR RESOLUTION
The Fen-Phen multidistrict litigation is one of the largest and longest-running mass-tort product-liability cases in U.S. history.
MEDICAL SCREENING FUND
Approximately $1 billion was set aside for medical refunds, testing, and screening costs for patients who took the diet drugs Pondimin (fenfluramine) or Redux (dexfenfluramine).
PERSONAL INJURY FUND
Approximately $2.55 billion was designated to compensate individuals diagnosed with heart-valve damage or related injuries.
GENERAL MOTORS IGNITION SWITCH
The General Motors ignition-switch multidistrict litigation was a massive federal proceeding combining hundreds of lawsuits involving a deadly vehicle defect.
The defect led to the recall of millions of vehicles, including models such as the Chevrolet Cobalt and Saturn Ion, and was linked to at least 124 deaths and numerous injuries.
General Motors paid billions of dollars in criminal penalties, federal settlements, and economic-loss settlements, including a $120 million driver settlement.
Our team successfully settled hundreds of clients' cases and family members' claims without going to trial.
C.R. BARD
APPROXIMATELY $1.6 BILLION IN CONFIDENTIAL GLOBAL SETTLEMENTS
This federal litigation was largely closed after resolving through confidential global settlements totaling approximately $1.6 billion.
COOK MEDICAL IVC FILTERS
The active federal IVC filter multidistrict litigation is MDL No. 2570 against Cook Medical, which has had more than 6,500 pending cases.
MESOTHELIOMA
HUNDREDS OF MILLIONS OF DOLLARS RECOVERED FOR CLIENTS
Mesothelioma is a rare and aggressive form of cancer that develops in the thin protective tissue lining the internal organs, known as the mesothelium.
Our firm, together with its partners, has recovered hundreds of millions of dollars for clients over the past three decades.
People affected by this disease and asbestos-related exposure include:
GADOLINIUM MDL
A federal MDL was created in the U.S. District Court for the Northern District of Ohio.
The litigation focused on cases involving nephrogenic systemic fibrosis (NSF), a rare and severe skin and organ condition linked to early contrast dyes in patients with severe kidney failure.
These cases eventually reached individual settlements or verdicts.
BENICAR
$300–$358 MILLION GLOBAL SETTLEMENT
The Benicar Multidistrict Litigation was a federal consolidation of lawsuits against manufacturer Daiichi Sankyo over severe gastrointestinal side effects caused by the blood-pressure medication Benicar (olmesartan).
The litigation was largely resolved in 2017 when Daiichi Sankyo agreed to a $300 million to $358 million global settlement to resolve more than 2,000 pending claims.
Most cases have since been dismissed or settled.
YASMIN AND YAZ
MORE THAN $2 BILLION PAID TO SETTLE MORE THAN 18,000 CLAIMS
The Yasmin multidistrict litigation was a consolidated federal lawsuit against manufacturer Bayer involving severe health risks linked to the birth-control pills Yasmin and Yaz.
Bayer reached major settlement agreements for claims involving blood clots and gallbladder complications.
Overall, Bayer has paid more than $2 billion to settle more than 18,000 claims consolidated within the MDL.
GRANUFLO / NATURALYTE
$250 MILLION GLOBAL SETTLEMENT
The litigation was centralized in the U.S. District Court for the District of Massachusetts.
The federal MDL and related state-court cases reached a major $250 million global settlement agreement in 2016 to resolve claims for eligible injured patients.
3M COMBAT ARMS EARPLUGS
$6.01 BILLION SETTLEMENT FRAMEWORK
The litigation was centralized in the U.S. District Court for the Northern District of Florida under Judge M. Casey Rodgers.
3M agreed to a $6.01 billion settlement framework, consisting of cash and restructured payouts, to resolve the litigation.
Payouts were distributed across a tiered injury scale ranging from $7,000 to $750,000.
Major litigation is rarely defined by a single case, a single defendant, or a single courtroom. It requires the ability to investigate complex facts, coordinate with litigation partners, confront well-funded defendants, and remain focused on the people whose lives have been affected.
That experience informs how eJustice approaches the matters it investigates today.
REQUEST A CONFIDENTIAL CASE EVALUATIONPrior results do not guarantee or predict a similar outcome. Every case is different and must be evaluated on its individual facts.
